ChemLifeIntel/Companies/Agios Pharmaceuticals

Agios Pharmaceuticals

HIGH RISKHQ: — · Private · Founded —

LISTINGPrivateFOUNDED0

FOCUS THERAPY AREAS

Manufacturer

COMPANY INTELLIGENCE SNAPSHOTlive

Manufacturing Sites

Intelligence Briefs

Active Regulatory Actions

—

HQ Country

NO ACTIVE REGULATORY ACTIONSClean compliance footprint across 0 monitored sites · HQ

View regulatory detail

INTELLIGENCE

Showing 2 of 2 briefs on Agios Pharmaceuticals

CLINICAL & PIPELINE·Phase 3 Completion

Agios Pharmaceuticals Halts Tebapivat Development for Sickle Cell Disease Amidst Mid-Stage Trial Disappointment

Agios Pharmaceuticals has halted mid-stage development of tebapivat for sickle cell disease due to insufficient differentiation, impacting its competitive position against Novo Nordisk. This setback elevates the commercial importance of Agios's mitapivat, which holds US FDA Priority Review for sickle cell with an approval decision expected by November 1. Procurement and supply chain leaders must monitor the volatile sickle cell market.

90-Day Activity

Agios Pharmaceuticalstebapivat

LVLakshmi Venkataraman· Senior Intelligence Analyst

7d ago Phase 3 Completion

CLINICAL & PIPELINE·Drug Approval

Agios Pharmaceuticals' Mitapivat Secures US FDA Priority Review for Sickle Cell Disease, Accelerating Market Entry

Agios Pharmaceuticals has received US FDA Priority Review for mitapivat in Sickle Cell Disease under Accelerated Approval, targeting a November 1, 2026 PDUFA. This fast-tracks market entry, demanding immediate strategic adjustments for procurement, regulatory, and business development teams. Stakeholders must prepare for expedited supply chain scaling, navigate accelerated approval complexities, and capitalize on early commercial opportunities in this high-unmet-need therapeutic area.

90-Day Activity

Agios PharmaceuticalsMitapivat

CMCatherine Morrow· Senior Regulatory Intelligence Analyst

21d ago Drug Approval